Cargando…
Advances and Limitations of Antibody Drug Conjugates for Cancer
The popularity of antibody drug conjugates (ADCs) has increased in recent years, mainly due to their unrivalled efficacy and specificity over chemotherapy agents. The success of the ADC is partly based on the stability and successful cleavage of selective linkers for the delivery of the payload. The...
Autores principales: | Mckertish, Candice Maria, Kayser, Veysel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389690/ https://www.ncbi.nlm.nih.gov/pubmed/34440076 http://dx.doi.org/10.3390/biomedicines9080872 |
Ejemplares similares
-
A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2023) -
Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy
por: Cruz, Esteban, et al.
Publicado: (2019) -
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016) -
Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation
por: Sifniotis, Vicki, et al.
Publicado: (2019) -
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)